1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Nanomix Corporation

Nanomix Corporation

NNMX
Nanomix CorporationUS flagOther OTC
0.00
USD
- -
- -
9,799.00Market Cap
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
0.05
- -
- -
- -
Basic EPS, GAAP
-5.05
-1.79
- -
-0.33
Free Cash Flow per Basic Share
-3.23
-1.26
- -
-0.16
Dividend per Share
- -
- -
- -
- -
Book Value per Share
-79.39
-20.15
- -
-3.17
Tangible Book Value per Share
-42.9
-4.09
- -
-0.37
Basic Weighted Avg Shares
1
5
- -
38
Sales/Revenue/Turnover
- -
- -
- -
- -
Operating Margin (%)
-8,126.48
- -
-54,609.5
-54,354.19
Depreciation Expense
- -
- -
- -
- -
Net Income, GAAP
-6
-9
-12
-12
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
-10,256.51
- -
-79,825.09
-79,569.54
Working Capital
-4
-3
-4
-4
LT Debt
9
4
10
10
Total Equity
-53
-22
-14
-14
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'22
Sep'22
Dec'22
ST Debt
1
1
1
LT Borrowings
6
8
10
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
48
49
Market Capitalization
15
10
7

Working Capital

FRC

•

in mil. unless spec.
Jun'22
Sep'22
Dec'22
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
4
Payables & Accruals
2
2
2
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-36.17%
Free Cash Flow
- -
- -
-8.13%
Net Income, GAAP
- -
- -
30.3%
Sales/Revenue/Turnover
- -
- -
-74.41%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
-5.05
2021
-0.99
-2.92
-0.47
- -
-1.79
2022
-0.15
-0.06
-0.08
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David Gerald Ludvigson
Full Time Employees
30
Sector
Healthcare
Industry
Medical - Devices
Address
354 Merrimack Street Lawrence MA United States of America 01843
IPO Date
Nov 22, 2021
CIK
0001473579
Website
bostonti.com
Similar Companies
Biotricity, Inc. (BTCY)
REMSleep Holdings, Inc. (RMSL)
Accuray Incorporated (ARAY)
Titan Medical Inc. (TMDI)
Avanos Medical, Inc. (AVNS)
Health & Life Co., Ltd. (1781.TWO)
Business
Nanomix Corporation (NNMX) develops and commercializes mobile point-of-care diagnostic systems utilizing nanoelectronic biosensor technology for rapid in vitro diagnostic testing in clinical and non-clinical settings. The company offers the Nanomix eLab System, a handheld, fully automated platform that delivers quantitative results through electrochemical immunoassays and enzymatic assays; key products include the S1 Panel for aiding in the diagnosis of critical infections such as sepsis and pneumonia via host response biomarkers, a C-reactive protein (CRP) test for evaluating infection, tissue injury, and inflammatory disorders, and a pipeline of assays targeting cardiac care, brain injury, and other time-critical conditions. Nanomix targets healthcare providers in hospitals, emergency departments, urgent care centers, nursing facilities, elderly homes, schools, airports, and emergency medical response environments, with operations focused primarily in the United States and expanding internationally through distribution partnerships. Founded in 2000 and headquartered in San Leandro, California, the company completed a reverse merger with Boston Therapeutics, Inc. in 2021, which facilitated an $8.4 million convertible note financing to support commercial scaling and manufacturing. Recent developments include the appointment of Christopher R. Hetterly as chief financial officer and multiple distribution agreements, such as with Gepa Srl in Italy, Woodley Equipment Company for global veterinary markets, Mast Group Limited for clinical, industrial, and veterinary testing in multiple regions, Diaclinic SpA in Chile, and IPS in the Middle East.